Mutual of America Capital Management LLC Sells 461 Shares of Solventum Co. (NYSE:SOLV)

Mutual of America Capital Management LLC cut its stake in Solventum Co. (NYSE:SOLV) by 2.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 16,592 shares of the company’s stock after selling 461 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Solventum were worth $1,096,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently made changes to their positions in the stock. Janney Montgomery Scott LLC grew its stake in shares of Solventum by 9.8% during the 3rd quarter. Janney Montgomery Scott LLC now owns 42,931 shares of the company’s stock valued at $2,993,000 after purchasing an additional 3,848 shares during the period. Van ECK Associates Corp grew its position in Solventum by 53.9% during the third quarter. Van ECK Associates Corp now owns 36,694 shares of the company’s stock valued at $2,660,000 after buying an additional 12,847 shares during the period. Robeco Institutional Asset Management B.V. grew its position in Solventum by 29.0% during the third quarter. Robeco Institutional Asset Management B.V. now owns 27,826 shares of the company’s stock valued at $1,940,000 after buying an additional 6,260 shares during the period. Asset Management One Co. Ltd. increased its holdings in Solventum by 0.9% during the third quarter. Asset Management One Co. Ltd. now owns 53,597 shares of the company’s stock valued at $3,737,000 after buying an additional 464 shares during the last quarter. Finally, Concurrent Investment Advisors LLC bought a new position in Solventum in the third quarter worth approximately $213,000.

Analyst Ratings Changes

Several research analysts have recently commented on the company. Morgan Stanley raised their price objective on Solventum from $73.00 to $80.00 and gave the stock an “equal weight” rating in a research note on Wednesday, March 5th. Bank of America lifted their target price on shares of Solventum from $80.00 to $85.00 and gave the company a “neutral” rating in a research note on Wednesday, February 26th. Mizuho lifted their target price on Solventum from $70.00 to $82.00 and gave the company a “neutral” rating in a research note on Monday, March 3rd. The Goldman Sachs Group raised their target price on shares of Solventum from $63.00 to $71.00 and gave the company a “sell” rating in a research note on Monday, March 3rd. Finally, Wells Fargo & Company increased their price target on Solventum from $73.00 to $75.00 and gave the company an “equal weight” rating in a research note on Friday, February 28th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and one has given a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $79.86.

Solventum Trading Up 2.9 %

SOLV stock opened at $77.96 on Monday. Solventum Co. has a twelve month low of $47.16 and a twelve month high of $85.92. The company has a quick ratio of 0.83, a current ratio of 1.15 and a debt-to-equity ratio of 2.45. The firm’s fifty day simple moving average is $73.65 and its two-hundred day simple moving average is $70.71. The stock has a market capitalization of $13.49 billion and a price-to-earnings ratio of 28.35.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.